Poseida Therapeutics, Inc. (PSTX)
Jan 8, 2025 - PSTX was delisted (reason: acquired by Roche)
9.50
0.00 (0.00%)
Inactive · Last trade price on Jan 7, 2025
Poseida Therapeutics Employees
Poseida Therapeutics had 330 employees as of December 31, 2023. The number of employees increased by 16 or 5.10% compared to the previous year.
Employees
330
Change (1Y)
16
Growth (1Y)
5.10%
Revenue / Employee
$457,145
Profits / Employee
-$184,118
Market Cap
928.85M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 330 | 16 | 5.10% |
| Dec 31, 2022 | 314 | 51 | 19.39% |
| Dec 31, 2021 | 263 | 57 | 27.67% |
| Dec 31, 2020 | 206 | 57 | 38.26% |
| Dec 31, 2019 | 149 | 97 | 186.54% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
PSTX News
- 23 days ago - Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company - GlobeNewsWire
- 7 months ago - Roche to complete acquisition of U.S. biopharma company Poseida - Reuters
- 8 months ago - Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting - PRNewsWire
- 9 months ago - POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX - Business Wire
- 9 months ago - Poseida shares triple on Tuesday, boosted by Roche collaboration - Invezz
- 9 months ago - Why This Gene-Therapy Company's Stock Is Rising 228% - Barrons
- 9 months ago - Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details - Benzinga
- 9 months ago - Roche to acquire US-based Poseida Therapeutics - Reuters